Published in Drug Metab Dispos on February 05, 2009
Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol (2014) 2.17
Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol (2013) 1.40
The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov (2010) 1.33
Laboratory assessment of rivaroxaban: a review. Thromb J (2013) 1.16
Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J (2013) 1.15
New anticoagulants: how to deal with treatment failure and bleeding complications. Br J Clin Pharmacol (2011) 1.11
Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet (2014) 1.05
Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol (2013) 0.98
Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol (2013) 0.93
Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. Clin Res Cardiol (2014) 0.92
A new era of stroke prevention in atrial fibrillation: comparing a new generation of oral anticoagulants with warfarin. Int Arch Med (2013) 0.86
Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban. Clin Pharmacokinet (2014) 0.86
Rivaroxaban and hemostasis in emergency care. Emerg Med Int (2014) 0.84
Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents. Europace (2012) 0.84
Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications. Drugs (2014) 0.83
Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes. Br J Clin Pharmacol (2012) 0.83
Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation. J Thromb Thrombolysis (2013) 0.83
Simplifying thromboprophylaxis could improve outcomes in orthopaedic surgery. Thrombosis (2010) 0.82
Anticoagulant therapy for patients with ischaemic stroke. Nat Rev Neurol (2012) 0.82
Reversal of oral anticoagulation. Pharmacotherapy (2013) 0.82
Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism. Thromb J (2014) 0.81
Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism. Vasc Health Risk Manag (2015) 0.81
Novel anticoagulants in atrial fibrillation stroke prevention. Ther Adv Chronic Dis (2012) 0.79
Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment. Thromb J (2014) 0.79
Reversal of target-specific oral anticoagulants. Drug Discov Today (2014) 0.78
Rivaroxaban and other non-vitamin K antagonist oral anticoagulants in the emergency treatment of thromboembolism. Int J Emerg Med (2013) 0.78
Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants (DOACs): A Systematic Review. Chest (2016) 0.78
Effects of factor Xa on the expression of proteins in femoral arteries from type 2 diabetic patients. Br J Clin Pharmacol (2014) 0.76
Supporting the use of a coagulometric method for rivaroxaban control: a hypothesis-generating study to define the safety cut-offs. Thromb J (2015) 0.76
Atrial fibrillation: a review of recent studies with a focus on those from the duke clinical research institute. Scientifica (Cairo) (2014) 0.76
Non-Vitamin K Antagonist Oral Anticoagulants: New Choices for Patient Management in Atrial Fibrillation. Am J Cardiovasc Drugs (2015) 0.75
The discovery of rivaroxaban: translating preclinical assessments into clinical practice. Front Pharmacol (2013) 0.75
Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins. Int J Mol Sci (2017) 0.75
Pharmacokinetics and Metabolism of Cyadox and Its Main Metabolites in Beagle Dogs Following Oral, Intramuscular, and Intravenous Administration. Front Pharmacol (2016) 0.75
A case-based approach to implementing guidelines for stroke prevention in patients with atrial fibrillation: balancing the risks and benefits. Thromb J (2015) 0.75
Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy. Ann Pharmacother (2016) 0.75
Atrial fibrillation management in older heart failure patients: a complex clinical problem. Heart Int (2016) 0.75
Potential role of rivaroxaban in patients with acute coronary syndrome. Drug Des Devel Ther (2012) 0.75
Population Pharmacokinetic and Pharmacodynamic Modeling Analysis of GCC-4401C, a Novel Direct Factor Xa Inhibitor, in Healthy Volunteers. CPT Pharmacometrics Syst Pharmacol (2016) 0.75
Supratherapeutic anticoagulation at presentation is associated with reduced mortality in nonvariceal upper gastrointestinal hemorrhage. Endosc Int Open (2014) 0.75
A Rare Case of Rivaroxaban Causing Delayed Symptomatic Hepatocellular Injury and Hyperbilirubinemia. Case Rep Gastrointest Med (2017) 0.75
New oral anticoagulants for thromboprophylaxis after elective total hip and knee arthroplasty. Thrombosis (2010) 0.75
Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin. Gastroenterol Res Pract (2016) 0.75
Patient compliance with new oral anticoagulants after major orthopaedic surgery: rivaroxaban and dabigatran compared with subcutaneous injection of fondaparinux. Joints (2017) 0.75
Selecting antithrombotic therapy for patients with atrial fibrillation. Cleve Clin J Med (2015) 0.75
Drug-induced liver injury: Towards early prediction and risk stratification. World J Hepatol (2017) 0.75
FXa inhibition by Rivaroxaban modifies mechanisms associated with the pathogenesis of human abdominal aortic aneurysms. Br J Clin Pharmacol (2017) 0.75
Use of rivaroxaban in patients with stroke. Neurol Sci (2017) 0.75
Genomics. Genome project standards in a new era of sequencing. Science (2009) 7.72
Molecular weights of coliphages and coliphage DNA. 3. Contour length and molecular weight of DNA from bacteriophages T4, T5 and T7, and from bovine papilloma virus. J Mol Biol (1970) 7.20
Construction and properties of an integrable plasmid for Bacillus subtilis. J Bacteriol (1983) 7.12
Simplified quantitative electron microscopy of biopolymers. Biopolymers (1970) 5.37
Nitrosopumilus maritimus genome reveals unique mechanisms for nitrification and autotrophy in globally distributed marine crenarchaea. Proc Natl Acad Sci U S A (2010) 4.12
Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother (1998) 3.60
Electron microscopy of size and shape of viral DNA in solutions of different ionic strengths. J Mol Biol (1967) 3.16
Immunoregulatory mechanisms involved in elicitation of allergic contact hypersensitivity. Immunol Today (1998) 3.12
Female mice heterozygous for IKK gamma/NEMO deficiencies develop a dermatopathy similar to the human X-linked disorder incontinentia pigmenti. Mol Cell (2000) 2.70
Human keratinocytes are a source for tumor necrosis factor alpha: evidence for synthesis and release upon stimulation with endotoxin or ultraviolet light. J Exp Med (1990) 2.62
Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother (1999) 2.37
Intracellular persistence of Staphylococcus aureus small-colony variants within keratinocytes: a cause for antibiotic treatment failure in a patient with darier's disease. Clin Infect Dis (2001) 2.14
The in vitro anticoagulant effect of rivaroxaban in children. Thromb Res (2012) 1.94
Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol Today (1995) 1.91
Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol (1999) 1.81
'Brain attack'--aneurysmal subarachnoid haemorrhage: death due to delayed diagnosis. J R Coll Physicians Lond (1997) 1.76
Ultraviolet light induces apoptosis via direct activation of CD95 (Fas/APO-1) independently of its ligand CD95L. J Cell Biol (1998) 1.75
Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost (2014) 1.74
Identification of binding sites for the 86-kilodalton IE2 protein of human cytomegalovirus within an IE2-responsive viral early promoter. J Virol (1994) 1.73
Shunt implantation: reducing the incidence of shunt infection. J Neurosurg (1992) 1.69
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
The immunogenic glycoprotein gp35-37 of human herpesvirus 8 is encoded by open reading frame K8.1. J Virol (1998) 1.66
Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther (2000) 1.58
The crystal structure of a hyper-thermophilic carboxylesterase from the archaeon Archaeoglobus fulgidus. J Mol Biol (2001) 1.58
IFN-beta 2, B cell differentiation factor 2, or hybridoma growth factor (IL-6) is expressed and released by human epidermal cells and epidermoid carcinoma cell lines. J Immunol (1989) 1.54
The diameter of coronary arteries in infants and children without heart disease. Eur J Pediatr (1989) 1.51
Use of identification cards by underage youth to purchase tobacco. JAMA (2001) 1.51
Heat shock protein 70 overexpression affects the response to ultraviolet light in murine fibroblasts. Evidence for increased cell viability and suppression of cytokine release. J Clin Invest (1995) 1.49
Evidence for an epidermal cytokine network. J Invest Dermatol (1990) 1.48
Migration of cardiac neural crest cells in Splotch embryos. Development (2000) 1.43
Ultraviolet light induces increased circulating interleukin-6 in humans. J Invest Dermatol (1990) 1.42
[Drug reaction to amoxicillin simulating toxic pustuloderma]. Hautarzt (1991) 1.42
Molecular mechanisms of UV-induced apoptosis. Photodermatol Photoimmunol Photomed (2000) 1.41
Diagnosis of bone infection using 99m Tc-HMPAO labelled leukocytes. Nucl Med Commun (2001) 1.40
Observation of B(0)(s)-->Psi(2S)Phi and measurement of the ratio of branching fractions Beta(B(0)(s)-->Psi(2S)Phi)/Beta(B(0)(s)-->J/PsiPhi). Phys Rev Lett (2006) 1.40
Prolonged akinetic mutism due to multiple sclerosis. J Neuropsychiatry Clin Neurosci (1995) 1.40
Safe paediatric neurosurgery 2001. Br J Neurosurg (2002) 1.40
Valve surgery combined with coronary artery operation: is the use of internal mammary artery a predictor for early complications? Eur J Cardiothorac Surg (1996) 1.39
The open conformation of a Pseudomonas lipase. Structure (1997) 1.39
Regulatory mechanisms in carbohydrate metabolism. IX. Stimulation of aerobic glycolysis by energy-linked ion transport and inhibition by dextran sulfate. J Biol Chem (1973) 1.35
Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor xa inhibitor--in healthy subjects. Int J Clin Pharmacol Ther (2007) 1.34
Denaturation map of bacteriophage T7 DNA and direction of DNA transcription. J Mol Biol (1972) 1.32
Regular superstructures of purified DNA in ethanolic solutions. J Mol Biol (1973) 1.31
Precision top-quark mass measurement at CDF. Phys Rev Lett (2012) 1.30
Proopiomelanocortin-derived peptides are synthesized and released by human keratinocytes. J Clin Invest (1994) 1.29
Folate improves endothelial function in coronary artery disease: an effect mediated by reduction of intracellular superoxide? Arterioscler Thromb Vasc Biol (2001) 1.29
Increased inorganic phosphate induces human endothelial cell apoptosis in vitro. Am J Physiol Renal Physiol (2008) 1.28
IFN-beta 2/IL-6 augments the activity of human natural killer cells. J Immunol (1989) 1.28
A snapshot of a transition state analogue of a novel thermophilic esterase belonging to the subfamily of mammalian hormone-sensitive lipase. J Mol Biol (2000) 1.25
Removal of the majority of epidermal Langerhans cells by topical or systemic steroid application enhances the effector phase of murine contact hypersensitivity. J Immunol (1995) 1.24
Molecular cloning of the spo0B sporulation locus in bacteriophage lambda. J Bacteriol (1982) 1.23
Validation of a volunteer model of cholera with frozen bacteria as the challenge. Infect Immun (1998) 1.23
UVB light induces nuclear factor kappa B (NF kappa B) activity independently from chromosomal DNA damage in cell-free cytosolic extracts. J Invest Dermatol (1994) 1.23
Apoptotic neurodegeneration following trauma is markedly enhanced in the immature brain. Ann Neurol (1999) 1.23
Measurement of the cross section for prompt isolated diphoton production using the full CDF run II data sample. Phys Rev Lett (2013) 1.22
Ultraviolet-B-induced apoptosis of keratinocytes: evidence for partial involvement of tumor necrosis factor-alpha in the formation of sunburn cells. J Invest Dermatol (1995) 1.20
Overexpression of CD40 ligand in murine epidermis results in chronic skin inflammation and systemic autoimmunity. J Exp Med (2001) 1.17
Regulation of epidermal cell interleukin-6 production by UV light and corticosteroids. J Invest Dermatol (1991) 1.17
Nuclear and cell membrane effects contribute independently to the induction of apoptosis in human cells exposed to UVB radiation. Proc Natl Acad Sci U S A (1999) 1.16
Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells. Immunology (1994) 1.16
The dodecahedral framework of the bacteriophage phi 6 nucleocapsid is composed of protein P1. J Virol (1987) 1.15
Collapse of single DNA molecules in ethanol. J Mol Biol (1969) 1.15
Dehydrated circular DNA: electron microscopy of ethanol-condensed molecules. J Mol Biol (1976) 1.15
UV-irradiated epidermal cells produce a specific inhibitor of interleukin 1 activity. J Immunol (1987) 1.15
A Dictyostelium mutant with severe defects in alpha-actinin: its characterization using cDNA probes and monoclonal antibodies. J Cell Sci (1988) 1.15
Expression of functional neutrophil-type NADPH oxidase in cultured rat coronary microvascular endothelial cells. Cardiovasc Res (1998) 1.14
Cross-linking Fc receptors on monocytes triggers IL-6 production. Role in anti-CD3-induced T cell activation. J Immunol (1990) 1.14
In vivo effects of interleukin-10 on contact hypersensitivity and delayed-type hypersensitivity reactions. J Invest Dermatol (1994) 1.14
Evidence for functional relevance of CTLA-4 in ultraviolet-radiation-induced tolerance. J Immunol (2000) 1.13
Osteogenesis imperfecta in childhood: cardiac and renal manifestations. Eur J Pediatr (1989) 1.13
Interleukin-12 prevents ultraviolet B-induced local immunosuppression and overcomes UVB-induced tolerance. J Invest Dermatol (1996) 1.13
Amines and a peptide as neurohormones in lobsters: actions on neuromuscular preparations and preliminary behavioural studies. J Exp Biol (1980) 1.13
Functional expression of the renin-angiotensin system in human podocytes. Am J Physiol Renal Physiol (2005) 1.12
Measurement of the WW + WZ production cross section using the lepton + jets final state at CDF II. Phys Rev Lett (2010) 1.12
Directed evolution of an enantioselective lipase. Chem Biol (2000) 1.11
Bipolar atrial sensing thresholds in sinus rhythm and atrial tachyarrhythmias. A comparative analysis in patients with DDDR pacemakers. Europace (1999) 1.11
Diffusion coefficient of DNA in solution at "zero" concentration as measured by electron microscopy. J Mol Biol (1968) 1.11
First observation of the decay Bs0-->Ds-Ds+ and measurement of its branching ratio. Phys Rev Lett (2008) 1.11
Endothelium-derived relaxing factor and nitroprusside compared in noradrenaline- and K+-contracted rabbit and rat aortae. J Physiol (1988) 1.11
Increased IL-6 production by monocytes and keratinocytes in patients with psoriasis. J Invest Dermatol (1991) 1.10
Intracellular pH and buffer curves of cardiac muscle in rats as affected by temperature. Respir Physiol (1973) 1.10
Electron microscopy of bacteriophage phi 6 nucleocapsid: two-dimensional image analysis. J Virol (1984) 1.08
Evidence for a particle produced in association with weak bosons and decaying to a bottom-antibottom quark pair in higgs boson searches at the tevatron. Phys Rev Lett (2012) 1.08
Electron microscopy of bacteriophage phi 6 nucleocapsid: three-dimensional image analysis. J Virol (1984) 1.08
Cancer-associated alteration of pericentromeric heterochromatin may contribute to chromosome instability. Oncogene (2011) 1.08
Search for supersymmetry at the LHC in events with jets and missing transverse energy. Phys Rev Lett (2011) 1.08
Measurement of sigma chi c2 B(chi c2-->J/psi gamma)/sigma chi c1 B(chi c1 -->J/psi gamma) in pp collisions at square root s=1.96 TeV. Phys Rev Lett (2007) 1.07
Search for stopped Gluinos in pp collisions at square root s=7 TeV. Phys Rev Lett (2011) 1.07
Short-term regulation of insulin gene transcription by glucose. Proc Natl Acad Sci U S A (1998) 1.07
Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J Immunol (2000) 1.07
Mechanisms involved in ultraviolet light-induced immunosuppression. J Investig Dermatol Symp Proc (1999) 1.07
Differential effects of NF-kappaB on apoptosis induced by DNA-damaging agents: the type of DNA damage determines the final outcome. Oncogene (2006) 1.06
Precise measurement of the W-boson mass with the CDF II detector. Phys Rev Lett (2012) 1.06
Neurotrophins and Trk receptors in human pancreatic ductal adenocarcinoma: expression patterns and effects on in vitro invasive behavior. Int J Cancer (1999) 1.05
Inhibition of the induction of contact hypersensitivity by a UV-mediated epidermal cytokine. J Invest Dermatol (1986) 1.05
Pro-opiomelanocortin-derived peptides induce IL-10 production in human monocytes. J Immunol (1996) 1.04
Direct measurement of the W production charge asymmetry in pp collisions at square root s=1.96 TeV. Phys Rev Lett (2009) 1.04
Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation. J Mol Biol (2000) 1.04